In addition to the standards in USP Chapter 800, the following requirements apply to a facility that compounds HDs or crushes or splits tablets or opens capsules of antineoplastic HDs.

Any facility where compounding of HDs is performed or where crushing or splitting tablets or opening capsules of antineoplastic HDs is performed shall ensure that all employees are aware of the types of HD exposures that may occur as referenced in USP Chapter 800. This shall be documented in SOPs and training documents.

Note: Authority cited: Sections 4005, 4126.8 and 4127, Business and Professions Code. Reference: Sections 4005 and 4126.8, Business and Professions Code.

History

1. New section filed 6-19-2025; operative 10-1-2025 (Register 2025, No. 25).